How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,301 results for

Myocardial Infarction Stabilization

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Management of Acute Myocardial Infarction During the COVID?19 Pandemic Full Text available with Trip Pro

, COVID‐19‐positive or probable patients with a non‐ST‐elevation acute myocardial infarction (NSTEMI) presentation should be managed medically and only taken for urgent coronary angiography and possible PCI in the presence of high‐risk clinical features (Global Registry of Acute Coronary Events [GRACE] score > 140) or hemodynamic instability. Patients with unstable angina or NSTEMI without high‐risk features can be initially managed with AMI guideline‐indicated medical therapies. Once stabilized (...) Management of Acute Myocardial Infarction During the COVID?19 Pandemic Management of acute myocardial infarction during the COVID‐19 pandemic - Mahmud - - Catheterization and Cardiovascular Interventions - Wiley Online Library COVID-19 campus closures: see options for to subscribed content. By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term Core Curriculum Free Access Management of acute myocardial infarction during

2020 Society for Cardiovascular Angiography and Interventions

2. Prasugrel besilate (Prasugrel Mylan) Acute Coronary Syndrome, Unstable Angina, Myocardial Infarction

Prasugrel besilate (Prasugrel Mylan) Acute Coronary Syndrome, Unstable Angina, Myocardial Infarction 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 22 March 2018 EMA/243820/2018 Committee for Medicinal Products for Human Use (...) Assessment Report FDA Food and Drug Administration GLP Good Laboratory Practice IC50 mean inhibitory concentration kg kilogram LD low dose LD50 mean lethal dose mg milligram mL milliliters NOAEL no observable adverse effect limit NSTEMI non-ST-elevation myocardial infarction PCI Percutaneous coronary intervention PPI proton pump inhibitor RBC red blood cells SBOA summary basis of approval SEM standard error of mean AS Active substance AR Assessment Report ASMF Active Substance Master File = Drug Master

2018 European Medicines Agency - EPARs

3. Management of Acute ST Segment Elevation Myocardial Infarction (STEMI) – (4th Edition)

Management of Acute ST Segment Elevation Myocardial Infarction (STEMI) – (4th Edition) CLINICAL PRACTICE GUIDELINE: MANAGEMENT OF ACUTE ST SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI) 4 th EDITION 2019 NATIONAL HEART ASSOCIATION OF MALAYSIA MOH/P/PAK/420.19(GU)-eMANAGEMENT OF ACUTE ST SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI) 2019 2 STATEMENT OF INTENT This guideline was developed to be a guide for best clinical practice, based on the best available evidence at the time of development (...) . CPG Secretariat Health Technology Assessment Unit Medical Development Division Level 4, Block EI, Parcel E Government Offices Complex 62590 Putrajaya, Malaysia Available on the following websites: http://www.moh.gov.my http://www.acadmed.org.myMANAGEMENT OF ACUTE ST SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI) 2019 3 MESSAGE FROM THE DIRECTOR GENERAL OF HEALTH The 1st Clinical Practice Guideline (CPG) on ST Elevation Myocardial Infarction (STEMI) was published in 2001 with a 2nd and 3rd update

2019 Ministry of Health, Malaysia

4. Myocardial infarction stabilization by cell‐based expression of controlled Vascular Endothelial Growth Factor levels Full Text available with Trip Pro

Myocardial infarction stabilization by cell‐based expression of controlled Vascular Endothelial Growth Factor levels Vascular Endothelial Growth Factor (VEGF) can induce normal or aberrant angiogenesis depending on the amount secreted in the microenvironment around each cell. Towards a possible clinical translation, we developed a Fluorescence Activated Cell Sorting (FACS)-based technique to rapidly purify transduced progenitors that homogeneously express a desired specific VEGF level from (...) ), but with an average similar to that of the SPEC population. A total of 70 nude rats underwent myocardial infarction by coronary artery ligation and 2 weeks later VEGF-expressing or control cells, or saline were injected at the infarction border. Four weeks later, ventricular ejection fraction was significantly worsened with all treatments except for SPEC cells. Further, only SPEC cells significantly increased the density of homogeneously normal and mature microvascular networks. This was accompanied by a positive

2018 Journal of cellular and molecular medicine

5. Management of Acute Myocardial Infarction in patients presenting with ST-segment elevation Full Text available with Trip Pro

Management of Acute Myocardial Infarction in patients presenting with ST-segment elevation We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation | European Heart Journal | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite (...) Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation 07 January 2018 Article Contents Article Navigation 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) Borja Ibanez (Chairperson) (Spain) * Corresponding authors

2017 European Society of Cardiology

6. Primary Percutaneous Coronary Intervention For Patients With ST-Elevation Myocardial Infarction (Focused Update): An Update of the Guideline For Percutaneous Coronary Intervention and the Guideline For the Management of ST-Elevation Myocardial Infarction

the MGuard for acute ST elevation reperfusion trial). Am J Cardiol. 2015;115:161–6. 43. Ali A, Cox D, Dib N, et al. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day resultsfromamulticenterrandomizedstudy.JAmColl Cardiol. 2006;48:244–52. 44. Migliorini A, Stabile A, Rodriguez AE, et al. Com- parison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute (...) Primary Percutaneous Coronary Intervention For Patients With ST-Elevation Myocardial Infarction (Focused Update): An Update of the Guideline For Percutaneous Coronary Intervention and the Guideline For the Management of ST-Elevation Myocardial Infarction FOCUSED UPDATE 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction AnUpdateofthe2011ACCF/AHA/SCAIGuideline for Percutaneous Coronary Intervention and the 2013ACCF

2015 American College of Cardiology

7. 2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non?ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures Full Text available with Trip Pro

2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non?ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures 2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures | Circulation (...) : Cardiovascular Quality and Outcomes Search Hello Guest! Login to your account Email Password Keep me logged in Search April 2019 March 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article 2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart

2017 American Heart Association

8. Interleukin‐6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID‐TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial Full Text available with Trip Pro

Interleukin‐6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID‐TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial Interleukin-6 (IL-6) is an inflammatory cytokine implicated in plaque instability in acute coronary syndrome (ACS). We aimed to evaluate the prognostic implications of IL-6 post-ACS.IL-6 concentration was assessed at baseline in 4939 subjects in SOLID-TIMI 52 (Stabilization (...) of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52), a randomized trial of darapladib in patients ≤30 days from ACS. Patients were followed for a median of 2.5 years for major adverse cardiovascular events; cardiovascular death, myocardial infarction, or stroke) and cardiovascular death or heart failure hospitalization. Primary analyses were adjusted first for baseline characteristics, days from index ACS, ACS type, and randomized treatment arm. For every SD increase in IL-6

2017 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

9. Predictors of Nonuse of a High‐Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib‐Thrombolysis in Myocardial Infarction 52 (SOLID‐TIMI 52) Trial Full Text available with Trip Pro

Predictors of Nonuse of a High‐Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib‐Thrombolysis in Myocardial Infarction 52 (SOLID‐TIMI 52) Trial High-potency statins reduce cardiovascular events after acute coronary syndromes but remain underused in clinical practice. We examined predictors of nonuse of high-potency statins after acute coronary syndromes.The Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial (...) Infarction (SOLID-TIMI 52) trial enrolled patients after an acute coronary syndrome in 36 countries between 2009 and 2011. Statin use was strongly encouraged throughout the trial, and statin potency was at the discretion of the treating physician. A high-potency statin was defined as ≥40 mg atorvastatin, ≥20 mg rosuvastatin, or 80 mg simvastatin daily. Predictors of nonuse of high-potency statins were examined using logistic regression. Of the patients included (n=12 446), 11 850 (95.2%) were treated

2017 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

10. Optimal Timing of Percutaneous Coronary Intervention in Patients With Non-ST-Segment Elevation Myocardial Infarction Complicated by Acute Decompensated Heart Failure (from the Korea Acute Myocardial Infarction Registry-National Institutes of Health [KAMIR (Abstract)

Optimal Timing of Percutaneous Coronary Intervention in Patients With Non-ST-Segment Elevation Myocardial Infarction Complicated by Acute Decompensated Heart Failure (from the Korea Acute Myocardial Infarction Registry-National Institutes of Health [KAMIR The optimal timing of percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation myocardial infarction (NSTEMI), complicated by acute decompensated heart failure (ADHF), is unclear. A total of 1,027 patients with NSTEMI (...) complicated by ADHF who underwent successful PCI were analyzed using a Korean multicenter registry. All patients were divided into 4 groups by the timing of PCI: group 1 (PCI < 2 hour after admission, n = 149), group 2 (2 to 24 hours, n = 577), group 3 (24 to 72 hours, n = 189), and group 4 (≥72 hours, n = 112). We analyzed the incidences of 12-month mortality, nonfatal myocardial infarction (MI), target-vessel revascularization, and rehospitalization because of HF. The prevalence of ADHF in patients

2018 American Journal of Cardiology

11. Sustained nicorandil administration reduces the infarct size in ST-segment elevation myocardial infarction patients with primary percutaneous coronary intervention. Full Text available with Trip Pro

Sustained nicorandil administration reduces the infarct size in ST-segment elevation myocardial infarction patients with primary percutaneous coronary intervention. Currently, there is still no effective strategy to diminish the infarct size (IS) in patients with ST-segment elevation myocardial infarction (STEMI). According to a previous animal study, nicorandil treatment is a promising pharmaceutical treatment to limit the infarct area. In this study, we aim to investigate the effects (...) completed the IS assessment via SPECT, and 99 participants were available for follow-up after 6 months. Finally, there was a statistical difference in the IS between the nicorandil and control groups {13% [interquartile range (IQR), 8-17] versus 16% [IQR, 12-20.3], p=0.027}. Additionally, we observed that maintained nicorandil administration significantly improved the left ventricular ejection fraction at 3 months and enhanced the activity tolerance (physical limitation and angina stability) at 6 months

2019 Anatolian journal of cardiology Controlled trial quality: uncertain

12. Myocardial Infarction Stabilization

Myocardial Infarction Stabilization Myocardial Infarction Stabilization Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Myocardial (...) Infarction Stabilization Myocardial Infarction Stabilization Aka: Myocardial Infarction Stabilization From Related Chapters II. Course: Hospital See Angiography, and stenting has modified the inpatient ACS protocol dramatically Prior protocols with prolonged hospital stays, ICU admits and prolonged have been replaced Evaluation prior to discharge prior to discharge Consider sub-maximal stress test prior to discharge See III. Disposition: Discharge Planning See See See IV. Complications (common) V

2018 FP Notebook

13. Comparison of 2-year clinical outcomes between diabetic versus nondiabetic patients with acute myocardial infarction after 1-month stabilization: Analysis of the prospective registry of DIAMOND (DIabetic acute myocardial infarctiON Disease) in Korea: an o Full Text available with Trip Pro

Comparison of 2-year clinical outcomes between diabetic versus nondiabetic patients with acute myocardial infarction after 1-month stabilization: Analysis of the prospective registry of DIAMOND (DIabetic acute myocardial infarctiON Disease) in Korea: an o This study assessed the 2-year clinical outcomes of patients with diabetes mellitus (DM) after acute myocardial infarction (AMI) in a cohort of the DIAMOND (DIabetic Acute Myocardial infarctiON Disease) registry. Clinical outcomes were (...) compared between 1088 diabetic AMI patients in the DIAMOND registry after stabilization of MI and 1088 nondiabetic AMI patients from the KORMI (Korean AMI) registry after 1 : 1 propensity score matching using traditional cardiovascular risk factors. Stabilized patients were defined as patients who did not have any clinical events within 1 month after AMI. Primary outcomes were the 2-year rate of major adverse cardiac events (MACEs), a composite of all-cause death, recurrent MI (re-MI), and target

2016 Medicine

14. Circulating Prolidase Activity in Patients with Myocardial Infarction Full Text available with Trip Pro

Circulating Prolidase Activity in Patients with Myocardial Infarction Collagen is a major determinant of atherosclerotic plaque stability. Thus, identification of differences in enzymes that regulate collagen integrity could be useful for predicting susceptibility to atherothrombosis or for diagnosing plaque rupture. In this study, we sought to determine whether prolidase, the rate-limiting enzyme of collagen turnover, differs in human subjects with acute myocardial infarction (MI) versus those

2017 Frontiers in cardiovascular medicine

15. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for t Full Text available with Trip Pro

2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for t 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA (...) Guideline for the Management of ST-Elevation Myocardial Infarction | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article 2015 ACC/AHA

2015 American Heart Association

16. Effectiveness and safety of recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction in elderly in combination with cardiac failure. Full Text available with Trip Pro

Effectiveness and safety of recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction in elderly in combination with cardiac failure. To investigate the effects and safety of recombinant human brain natriuretic peptide (rhBNP) in the treatment of elderly acute myocardial infarction induced cardiac failure.One hundred and forty-six patients who were diagnosed as elderly acute myocardial infarction induced cardiac failure in the hospital from July 2014 to July (...) effectively relieve the clinical symptoms, cardiac function indexes and hemodynamic indexes of patients with elderly acute myocardial infarction induced cardiac failure, with a high safety. It can be extensively applied in the treatment of acute myocardial infarction in combination with cardiac failure.

2019 Pakistan Journal Of Medical Sciences Controlled trial quality: uncertain

17. Association Between Secondary Prevention Medication Use and Outcomes in Frail Older Adults After Acute Myocardial Infarction. Full Text available with Trip Pro

or 4 medications, respectively. Rehospitalization odds ratios were 1.00 (95% CI, 0.85-1.17) for 2 and 0.97 (95% CI, 0.8-1.17) for 3 or 4 medications. Functional decline odds ratios were 1.04 (95% CI, 0.85-1.28) for 2 and 1.12 (95% CI, 0.89-1.40) for 3 or 4 medications. In a stability analysis excluding antiplatelet drugs from the exposure definition, more medication use was associated with functional decline. Conclusions Use of more guideline-recommended medications after myocardial infarction (...) Association Between Secondary Prevention Medication Use and Outcomes in Frail Older Adults After Acute Myocardial Infarction. Background Secondary prevention medications are often not prescribed to frail, older adults following acute myocardial infarction, potentially because of the absence of data to support use, perceived lack of benefit, and concern over possible harms. We examined the effect of using more guideline-recommended medications after myocardial infarction on mortality

2019 Circulation. Cardiovascular quality and outcomes

18. Acute myocardial infarction in a Chinese patient with paroxysmal nocturnal hemoglobinuria: A case report. Full Text available with Trip Pro

and CD59 were lost on the surface of the blood cells. Thus, our diagnosis of this patient was AMI secondary to PNH.For the first myocardial infarction, local hospitals used thrombolytic therapy to alleviate symptoms. After the patient's second myocardial infarction was treated in our hospital, we adopted coronary interventional therapy. Considering the patient's situation, eculizumab was given for treatment. The patient was gradually restored to achieve stability, and the follow-up observation showed (...) Acute myocardial infarction in a Chinese patient with paroxysmal nocturnal hemoglobinuria: A case report. Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disease. Patients with PNH often experience a high incidence (14%-40%) of thrombotic events, which are mainly venous and rarely arterial thrombotic events. Because it is very rare, delay in diagnosis is common in patients with PNH, imposing a remarkable impact on patient's management and prognosis.We presented

2019 Medicine

19. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. Full Text available with Trip Pro

to 1.03; P=0.07). The time to hemodynamic stabilization, the risk of catecholamine therapy and the duration of such therapy, the levels of troponin T and creatine kinase, and the rates of bleeding and stroke did not differ significantly between the two groups.Among patients who had multivessel coronary artery disease and acute myocardial infarction with cardiogenic shock, the 30-day risk of a composite of death or severe renal failure leading to renal-replacement therapy was lower among those who (...) PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. In patients who have acute myocardial infarction with cardiogenic shock, early revascularization of the culprit artery by means of percutaneous coronary intervention (PCI) improves outcomes. However, the majority of patients with cardiogenic shock have multivessel disease, and whether PCI should be performed immediately for stenoses in nonculprit arteries is controversial.In this multicenter trial, we randomly

2017 NEJM Controlled trial quality: predicted high

20. Acute Myocardial Infarction in patients presenting with ST-segment elevation

Acute Myocardial Infarction in patients presenting with ST-segment elevation ESC GUIDELINES ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) Authors/Task Force Members: Ph. Gabriel Steg (Chairperson) (France)*, Stefan K. James (Chairperson) (Sweden) * , Dan Atar (Norway), Luigi P. Badano (Italy), Carina (...) -- -- --- -- -- --- -- --- -- -- --- -- -- --- -- -- --- -- -- --- -- -- --- -- --- -- -- --- -- -- --- --- - - - - - - --- -- -- --- -- -- --- -- --- -- -- --- -- -- --- -- -- --- -- -- --- -- -- --- -- --- -- -- -- Keywords Guidelines † Acute myocardial infarction † ST-segment elevation † Acute coronary syndromes Ischaemic heart disease † Reperfusion therapy † Primary percutaneous coronary intervention Antithrombotic therapy † Secondary prevention Table of Contents Abbreviations and Acronyms . . . . . . . . . . . . . . . . . . . . . . . 2570 1. Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2572 2. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2573

2012 European Society of Cardiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>